Stemline Therapeutics, Inc. (NASDAQ:STML) has received a consensus rating of “Buy” from the nine research firms that are presently covering the company, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell rating and seven have issued a buy rating on the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $33.40.

STML has been the subject of several research analyst reports. HC Wainwright set a $34.00 price objective on shares of Stemline Therapeutics and gave the stock a “buy” rating in a report on Wednesday, August 9th. ValuEngine downgraded shares of Stemline Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, August 10th. Finally, Cowen reaffirmed a “buy” rating on shares of Stemline Therapeutics in a report on Tuesday, October 31st.

A number of institutional investors have recently modified their holdings of the business. Empire Life Investments Inc. bought a new stake in Stemline Therapeutics in the third quarter worth about $373,000. Cowen Inc. bought a new stake in Stemline Therapeutics in the third quarter worth about $420,000. Lyon Street Capital LLC raised its position in Stemline Therapeutics by 331.1% in the third quarter. Lyon Street Capital LLC now owns 541,462 shares of the biopharmaceutical company’s stock worth $6,010,000 after acquiring an additional 415,867 shares in the last quarter. Dimensional Fund Advisors LP raised its position in Stemline Therapeutics by 82.0% in the third quarter. Dimensional Fund Advisors LP now owns 219,252 shares of the biopharmaceutical company’s stock worth $2,434,000 after acquiring an additional 98,775 shares in the last quarter. Finally, C WorldWide Group Holding A S bought a new stake in Stemline Therapeutics in the third quarter worth about $1,776,000. Hedge funds and other institutional investors own 50.24% of the company’s stock.

Stemline Therapeutics (NASDAQ STML) traded down $0.40 during mid-day trading on Friday, reaching $15.15. 192,535 shares of the company traded hands, compared to its average volume of 275,924. Stemline Therapeutics has a 1-year low of $5.50 and a 1-year high of $15.95.

TRADEMARK VIOLATION NOTICE: “Brokerages Set Stemline Therapeutics, Inc. (STML) Price Target at $33.40” was reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this report on another website, it was copied illegally and reposted in violation of US and international copyright legislation. The correct version of this report can be accessed at https://theolympiareport.com/2017/12/05/brokerages-set-stemline-therapeutics-inc-stml-price-target-at-33-40.html.

About Stemline Therapeutics

Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.

Analyst Recommendations for Stemline Therapeutics (NASDAQ:STML)

Receive News & Ratings for Stemline Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.